Loading...
Docoh

Idera Pharmaceuticals (IDRA)

Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

IDRA stock data

Calendar

5 May 22
9 Aug 22
31 Dec 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.99M 27.99M 27.99M 27.99M 27.99M 27.99M
Cash burn (monthly) 1.52M 1.38M 1.39M 1.82M 1.52M 1.63M
Cash used (since last report) 6.53M 5.94M 6M 7.83M 6.55M 7.02M
Cash remaining 21.46M 22.06M 21.99M 20.16M 21.44M 20.97M
Runway (months of cash) 14.1 16.0 15.8 11.1 14.1 12.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 Jul 22 Kirby John J. Stock Option Common Stock Grant Acquire A No No 0.4327 66,500 28.77K 66,500
6 Jul 22 Milano Vincent Stock Option Common Stock Grant Acquire A No No 0.4327 124,000 53.65K 124,000
6 Jul 22 Soland Daniel B Stock Option Common Stock Grant Acquire A No No 0.4327 66,500 28.77K 66,500
6 Jul 22 Lim Bryant David Stock Option Common Stock Grant Acquire A No No 0.4327 66,500 28.77K 66,500
1 Jul 22 Dougherty Michael R Common Stock Grant Acquire A No No 0.438 50,086 21.94K 283,116
42.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 33 36 -8.3%
Opened positions 4 3 +33.3%
Closed positions 7 17 -58.8%
Increased positions 4 8 -50.0%
Reduced positions 9 7 +28.6%
13F shares Current Prev Q Change
Total value 22.98M 23.53M -2.3%
Total shares 22.55M 23.07M -2.2%
Total puts 0 0
Total calls 76.3K 114.9K -33.6%
Total put/call ratio
Largest owners Shares Value Change
Pillar Pharmaceuticals 6 16.75M $19.93M 0.0%
Castellina Ventures 2.2M $1.25M 0.0%
Vanguard 1.33M $664K -15.8%
BLK Blackrock 555.4K $277K -1.0%
Acadian Asset Management 457.1K $228K -9.7%
Geode Capital Management 373.48K $186K 0.0%
MS Morgan Stanley 127.07K $64K +0.7%
Group One Trading 112.4K $56K +68.0%
STT State Street 109.74K $55K 0.0%
Commonwealth Equity Services 86.66K $43K 0.0%
Largest transactions Shares Bought/sold Change
Vanguard 1.33M -248.95K -15.8%
Citadel Advisors 40.73K -171.09K -80.8%
Assenagon Asset Management 54.77K +54.77K NEW
Acadian Asset Management 457.1K -49.28K -9.7%
Millennium Management 0 -48.57K EXIT
Jane Street 0 -48.4K EXIT
VIRT Virtu Financial 46.37K +46.37K NEW
Two Sigma Advisers 0 -46.35K EXIT
Group One Trading 112.4K +45.5K +68.0%
Johnson Investment Counsel 42.13K +42.13K NEW

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: alternative, array, comparison, cure, deficiency, favourable, headcount, inception, January, Leadership, letter, minimum, modification, noncompliance, noteworthy, notification, notifying, prohibiting, protection, RSU, showed, team, threshold, traditional, translated, written
Removed: abnormal, accomplishment, activating, administering, AEs, affecting, amortized, announce, approach, assuming, attrition, blinded, cancer, care, case, central, challenge, chemotherapy, cohort, colorectal, commercializing, complementary, composition, contemporaneously, controlled, CRC, criteria, cutoff, cutting, decided, declared, decline, deducted, demand, demonstrated, dendritic, departed, depend, depository, design, developmental, difficult, disappointing, discover, distributing, dosage, dosing, dramatically, driven, durable, earliest, eliminated, employing, enrolled, era, event, execute, expand, expanded, experienced, expertise, family, FDA, fluctuate, frequency, function, group, heavily, heralded, hire, immature, immunosuppressive, implement, improve, increasing, initially, injected, instability, intratumorally, investigate, involvement, knowledge, life, line, litigation, low, median, metastatic, mg, microenvironment, microsatellite, mismatch, monotherapy, morale, MSS, multicohort, multiple, objective, oncology, order, organizational, OS, pembrolizumab, percentage, pertaining, pipeline, pivotal, population, produce, progressed, progressing, prospectively, randomization, rapidly, rationale, realization, realized, reallocate, receiving, recent, receptor, RECIST, reduction, regimen, registration, reimbursement, relapsed, remain, repair, replacement, requiring, responding, response, restructuring, reversal, review, secondary, serve, shelf, single, stability, stable, standard, state, stepwise, streamline, succeed, successful, supply, survival, system, target, targeted, therapeutic, TLR, TME, tolerated, topline, treated, triplet, tumor, unanticipated, unforeseen, uninjected, unintended, unsuccessful, variety, volatile, volatility, workforce, yield